Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q3 2019 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q3 2018 Net Income-$7.13M-$7.13MN/M vs Q3 2018 EPS Diluted-$0.66-$0.66N/M vs Q3 2018 Operating Income-$7,187,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,824,000N/M Free Cash Flowderived-$3,727,000— ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end